Actin vs altRX
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Actin
Best for affordable compounded semaglutide with B12 enhancementStarting at $133/mo
altRX
Best for Buyers who want the broadest possible brand-name FDA-approved GLP-1 access on a single platform — altRX is the only provider in the WLR directory offering all four (Mounjaro / Ozempic / Wegovy / Zepbound) alongside compounded options. Strong fit for patients who may switch between compounded and brand-name depending on response, supply, or insurance situation.Starting at $149/mo
Side-by-Side Comparison
| Feature | Actin | altRX |
|---|---|---|
| Overall Score | 7.0/10 | ✓7.3/10 |
| Starting Price | ✓$133/mo | $149/mo |
| Editorial Rating | 3.5 ★ /5 | ✓3.7 ★ /5 |
| Features | 2 features | ✓13 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Actin
Pros
- ✓Semaglutide + B12 combination for added energy support
- ✓Transparent pricing — exact cost shown upfront with no hidden fees
- ✓Competitive starting price from $133
Cons
- ✗Semaglutide only — no tirzepatide or liraglutide
- ✗No visible LegitScript or PCAB accreditation
- ✗State availability not disclosed
- ✗Broader platform (hormones, sexual wellness, hair health)
altRX
Pros
- ✓**ALL FOUR brand-name FDA-approved GLP-1s offered** (Mounjaro, Ozempic, Wegovy, Zepbound) — the most comprehensive brand-name access in the WLR directory. Most dual-modality competitors offer only 1-2 brand-name options; altRX covers the full FDA-approved set.
- ✓LegitScript Certified with publicly verifiable ID (48475686)
- ✓Verbatim FDA compounded-medication disclaimer published — meets WLR transparency standard
- ✓Pricing transparent across all 6 product tiers (compounded + 4 brand-name)
- ✓All-inclusive pricing (consult + prescription + shipping) — no hidden fees framing
- ✓Corporate structure disclosed (CareGLP Affiliated P.C.s + CareValidate Health) — Professional Corporation designation visible
- ✓1-day approval framing — faster than typical 24-72hr competitors
- ✓Brand-name pricing competitive vs retail cash-pay ($1,149-$1,579 vs $1,350-$1,400 typical retail)
Cons
- ✗States-served list NOT disclosed publicly
- ✗Specific 503A/503B pharmacy partner NOT named (only 'multiple USA-certified pharmacies' generic)
- ✗503A vs 503B compounding designation NOT specified
- ✗Named medical director NOT disclosed
- ✗Corporate physical address NOT disclosed
- ✗Governing law / arbitration venue NOT disclosed
- ✗Refund policy linked but full text not browsed
- ✗Brand-name pricing is cash-pay only (no insurance pathway) — patients with commercial Wegovy/Ozempic coverage should price-check elsewhere first
- ✗'CareGLP Affiliated P.C.s' framing is unusual — affiliated-PC structure may indicate state-by-state professional corporation setup vs single national entity
Our Verdict
altRX edges out Actin with a higher overall score of 7.3/10 and is particularly strong for Buyers who want the broadest possible brand-name FDA-approved GLP-1 access on a single platform — altRX is the only provider in the WLR directory offering all four (Mounjaro / Ozempic / Wegovy / Zepbound) alongside compounded options. Strong fit for patients who may switch between compounded and brand-name depending on response, supply, or insurance situation.. Actin remains a solid alternative, especially if you're looking for affordable compounded semaglutide with B12 enhancement.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.